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Purpose: Three new oral anticoagulants (NOACs)
have recently become available in the United Kingdom as
an alternative to warfarin in the prevention of stroke and
systemic embolism in atrial ﬁbrillation. This study exam-
ines the relative cost-effectiveness of dabigatran (BID
dosing of 150 mg or 110 mg based on patient age),
rivaroxaban, and apixaban from a UK payer perspective.
Methods: A previously published model that follows
up patients through treatment of atrial ﬁbrillation
during a lifetime was adapted to allow comparison of
the 3 NOACs and warfarin. Acute thromboembolic and
bleeding events, as well as long-term consequences of
stroke, intracranial hemorrhage, and acute myocardial
infarction, were tracked. Relative efﬁcacy was calcu-
lated from a formal indirect treatment comparison using
data from the 3 key trials (Randomized Evaluation of
Long-Term Anticoagulation Therapy, Rivaroxaban
Once-daily oral direct factor Xa inhibition Compared
with vitamin K antagonism for prevention of stroke and
Embolism Trial in Atrial Fibrillation, and Apixaban for
the Prevention of Stroke in Subjects With Atrial
Fibrillation) of the NOACs. Data from the rivaroxaban
trial were adjusted for the difference in international
normalized ratio control among warfarin patients ver-
sus the other 2 trials. Model outputs included total
costs, event rates, and quality-adjusted life-years.
Findings: Among the patients taking NOACs, those
taking dabigatran had the highest total QALYs (7.68
QALYs), followed by apixaban (7.63 QALYs) and
rivaroxaban (7.47 QALYs). Patients taking dabigatran
had the lowest total lifetime costs (£23,342), followed by
apixaban (£24,014) and rivaroxaban (£25,220). The
differences between dabigatran and apixaban wereDecember 2014modest but consistent in sensitivity analyses, with the
directionality only changing at the limits of the CIs for the
relative risks of ischemic stroke or intracranial hemor-
rhage or when assuming that both treatment discontin-
uation and post-event disability rates differ by drug.
Implications: Dabigatran was found to be econom-
ically dominant over rivaroxaban and apixaban in the
UK setting. These economic ﬁndings are based on
relative clinical efﬁcacy from an indirect treatment
comparison and would beneﬁt from any data of direct
comparisons of the NOACs in the future. (Clin Ther.
2014;36:2015–2028) & 2014 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: anticoagulation, apixaban, atrial ﬁbril-
lation, cost-effectiveness, dabigatran, rivaroxaban.INTRODUCTION
Atrial ﬁbrillation (AF) is the most common cardiac
arrhythmia and the leading cause of stroke in the
United Kingdom and across Europe.1 In patients with
AF, 80% of ischemic stroke (IS) events result in death
or disability and 1-year mortality approaches 50%.2,3
Vitamin K antagonists, such as warfarin, can be
highly effective in preventing stroke in patients with
AF. However, vitamin K antagonists are challenging
to use in clinical practice because they produce high
variability in dose responses because of genetic and2015
Clinical Therapeuticsother factors and are subject to numerous food and
drug interactions, resulting in the need for intensive
laboratory monitoring.4 These issues had considerably
limited initiation and subsequent persistence with
vitamin K antagonist treatment among AF patients
in the United Kingdom.5
Recently, new oral anticoagulants (NOACs), clas-
siﬁed as direct thrombin inhibitors (dabigatran etex-
ilate) and factor Xa inhibitors (rivaroxaban and
apixaban), have been approved and recommended
for treatment of AF in the United Kingdom.6–8
Evidence suggests that NOACs are at least as effective
as warfarin for the prevention of stroke and systemic
embolism in patients with AF and have a more
favorable proﬁle regarding fatal and major bleeding.9
Three Phase III trials evaluated the clinical efﬁcacy
and tolerability of dabigatran 150 mg BID and 110
mg BID (Randomized Evaluation of Long-Term Anti-
coagulation Therapy [RE-LY]), apixaban (Apixaban
for the Prevention of Stroke in Subjects With Atrial
Fibrillation [ARISTOTLE]), and rivaroxaban (Rivar-
oxaban Once-daily oral direct factor Xa inhibition
Compared with vitamin K antagonism for prevention
of stroke and Embolism Trial in Atrial Fibrillation
[ROCKET-AF]) during a median follow-up period of
2 years. These trials indicated superiority of dabiga-
tran 150 mg (1.11% vs 1.71% per year; P o
0.001)10,11 and apixaban (1.27% vs 1.60% per year;
P = .01)12 and noninferiority of dabigatran 110 mg
(1.54% vs 1.71% per year; P ¼ .30)10,11 and
rivaroxaban (2.1% vs 2.4% per year; P = .12)13
versus dose-adjusted warfarin on the primary outcome
of stroke or systemic embolism. Apixaban and dabi-
gatran 110 mg also had an effect on major bleeding
versus dose-adjusted warfarin, with a relative risk
(RR) reduction of 0.69 (P o 0.001) and 0.80 (P ¼
0.003), respectively.12
With 3 NOACs approved and reimbursed in the
United Kingdom, there is an increasing interest among
various stakeholders to understand the relative clinical
efﬁcacy and cost-effectiveness among them. Although
the long-term clinical and cost-effectiveness of these
NOACs versus standard of care (including aspirin and
no treatment) or dose-adjusted warfarin has been
assessed by several studies using simulation models
in the UK setting, similar studies comparing all the
NOACs are limited. The present study aims to address
this knowledge gap. The relative clinical efﬁcacy of
dabigatran, rivaroxaban, and apixaban was evaluated2016through an indirect treatment comparison (ITC),
where the differences among the trial population were
statistically adjusted to the RE-LY trial population. A
cost-effectiveness model was developed based on a
previously published framework to assess the relative
beneﬁt of the treatments during patients’ lifetimes.METHODS
Model Design
A Markov model with 3-month model cycles was
used to simulate patients with AF starting treatment
and followed up for their lifetime from the perspective
of the UK National Health Service, considering direct
costs only. Both cost and health outcomes were
discounted at 3.5% per annum in the model’s base
case, as recommended by the National Institute of
Health and Care Excellence (NICE).14 Dabigatran
dosing in the model corresponded to the approved
UK dosing, in which patients switch from the 150 mg
BID dose to the 110 mg BID dose on reaching age 80
years. Similarly, the approved UK dosing for apixaban
(5 mg BID) and rivaroxaban (20 mg once daily) was
used in the model, and the effect of dose reduction in
certain populations (eg, impaired renal function) was
assumed to be captured implicitly within the trial data.Model Structure
The current model expanded on a previously
published model.15,16 The clinical events considered
included primary and recurrent IS, systemic embolism,
acute myocardial infarction (AMI), transient ischemic
attack (TIA), intracranial hemorrhage (ICH) (includ-
ing hemorrhagic stroke [HS] and major extracranial
hemorrhage [ECH]), minor bleeding, and death. The
IS risk was stratiﬁed by patients’ CHADS2 score
17
(Congestive heart failure, Hypertension, Age 475
years, Diabetes, and prior Stroke) and stroke history
in each model cycle. As in the previously published
model, nonfatal IS and ICH can result in disability
(independent, moderately dependent, or totally
dependent) based on the post-event modiﬁed Rankin
Score for IS and the Glasgow Outcome Scale for
ICH.18 The previous model was updated to consider
the effect of AMI history, which would increase the
risk of future AMI19 and also result in long-term
quality of life and cost effects.Volume 36 Number 12
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The base case patient population in this model
reﬂected the RE-LY population characteristics.10 The
mean age of the patient population at model entry was
71 years, among whom 63.6% were male and 16.6%
had a history of AMI. Baseline CHADS2 score
distribution is presented in Table I, and all patients
entered the model as independent in terms of
disability level.
The warfarin arm of the RE-LY trial was used as
the reference arm for clinical event risks. The event
rates for other comparators were derived by applying
a RR to the warfarin rates. Clinical events were
deﬁned fairly consistently across the 3 major trials.
The RR was computed through an ITC using a
method published by Bucher et al,20 in which dose-
adjusted warfarin was used as a common comparator
among all 3 clinical trials (details of the ITC are
available in the Supplemental Appendix in the online
version at http://dx.doi.org/10.1016/j.clinthera.2014.
09.015). To match the approved indication in the
United Kingdom, the dabigatran data included in
these analyses combined data from the 2 RE-LY
dabigatran treatment arms, based on patient age at
randomization, to form a single dabigatran treatment
group. Speciﬁcally, this set (n ¼ 5990) combined
patients agedo80 years from the dabigatran 150 mg
BID group (n ¼ 5019/6076) and patients aged Z80
years from the dabigatran 110 mg BID group
(n ¼ 971/6015) (Boehringer Ingelheim, data on ﬁle).Table I. Patient Baseline CHADS2 Score Distrib-
ution and Stroke History
CHADS2
Score
CHADS2
Distribution, %
Previous
Stroke, %
0 2.5 0
1 29.4 0
2 35.6 6
3 20.2 37
4 8.9 81
5 2.9 100
6 0.5 100
CHADS2 ¼ Congestive heart failure, Hypertension, Age
475 years, Diabetes, and prior Stroke.17
December 2014Because the patient age, CHADS2 score, and interna-
tional normalized ratio (INR) control were similar
between the RE-LY population and the ARISTOTLE
population, no adjustment for these characteristics
was needed in the ITC. However, the ROCKET-AF
population was on average older, had higher
CHADS2 scores, and achieved worse INR control
compared with the RE-LY population. The mean
time in therapeutic range (TTR) in the warfarin arms
of the RE-LY and ARISTOTLE trials was similar
(64.4% and 62.2%, respectively), but it was worse
for the ROCKET-AF trial (55.2%). Given that poor
INR control was associated with higher risk of
clinical events,21 it was necessary to adjust the
ROCKET-AF estimates of events in the warfarin
arm, and thus the RR of events between rivaroxaban
and warfarin, to account for this difference in TTR.
The difference in TTR between the warfarin arms of
the RE-LY and ROCKET-AF trials were taken from
an analysis conducted by the Division of Biometrics
of the Food and Drug Administration in which the
ROCKET-AF trial population was adjusted by dem-
ographic, disease-related, and geographic factors to
the RE-LY population, leaving a residual difference
in TTR of 6.7%.22 To adjust for the remaining
difference in the TTR, an adjustment factor was
applied to the event rate in the warfarin arm of the
ROCKET-AF trial. The methods followed for mak-
ing the TTR adjustment have been described previ-
ously.23 Brieﬂy, the event rates for each type of
clinical event in the warfarin arm of the ROCKET-
AF trial were calculated. Each event rate for the
warfarin arm was then adjusted to account for the
6.7% difference in TTR by applying an odds ratio
for every 10% difference in TTR, which was esti-
mated using logistic regression of the warfarin arm in
the RE-LY trial as presented previously.23 Finally,
the adjusted RR of rivaroxaban versus warfarin was
calculated by dividing the event rate in the ROCKET-
AF rivaroxaban arm by the corresponding adjusted
event rate from the warfarin arm. The ITC was
conducted for the safety-on-treatment (SOT) popu-
lation when data were available; otherwise (TIA,
AMI, and minor bleeding) intent-to-treat data were
used. The ARISTOTLE trial reported the composite
event rate for stroke or systemic embolism in the
SOT population but not the individual event rate for
IS and systemic embolism, respectively.24 The event
rates were derived for these 2 events from the2017
Clinical Therapeuticscomposite event rate, assuming that the event
composition in the SOT population was the same
as in the intent-to-treat population.12 The clinical
event rates for the reference arm and the results of
the ITC are summarized in Table II.
The ICH events resulted in discontinuation of
current treatment. Patients could also discontinue
for other reasons, including ECH and nonclinical
reasons such as patient’s decision. Treatment dis-
continuation for all comparators was modeled using
a Weibull function that estimated 14% discontinua-
tion in 1 year and 21% discontinuation in 2 years,
closely replicating the RE-LY trial outcome. Al-
though the proportion of patients reported to dis-
continue treatment in the Phase III trials were differ-
ent (21% for dabigatran vs 17% for warfarin, 24%
for rivaroxaban vs 22% for warfarin, and 25% for
apixaban vs 28% for warfarin within approximately
2 years of follow-up), the differences in trial design
made it infeasible to perform a cross-trial compar-
ison, so all NOAC treatments were assumed to have
a 21% discontinuation rate by the end of the second
year.10,12,13 All patients who discontinued anticoa-
gulant therapy for other reasons were assumed to
switch to aspirin, and patients who discontinued
aspirin therapy were assumed to permanently dis-
continue all treatment. The event risks while patients
were receiving aspirin therapy or no treatment were
derived by applying RRs25 to the warfarin event rate
(Table II). Patients remain subject to short-term event
costs and long-term disability costs after switching to
aspirin therapy or no treatment.
Both ICH and IS can be disabling or fatal events.
On the basis of the NICE Evidence Review Group
report on a recent manufacturer submission of a
NOAC,26 it was assumed that the post-event
outcome for ICH and IS was not affected by the
selection of treatment. On the basis of the RE-LY trial,
4.3% of the patients were totally dependent, 19.7%
were moderately dependent, 53.9% were independent
after IS events, and the rest experienced fatal events.
Post ICH events, 31.8% of the patients were totally
dependent, 8.8% were moderately dependent, 7.8%
were independent, and the rest experienced fatal
events.
Clinical events in this model can be fatal with the
exception of TIA and minor bleeding. In addition to
the post-event mortality, the UK population back-
ground mortality (adjusted to avoid double-counting)2018was also applied to the model population. Patients
with a moderate to totally dependent disability level
were assumed to have double the background
mortality.27
Cost Inputs
Dabigatran (110 mg and 150 mg) and apixaban
were priced at £65.90 per 30-day supply, whereas
rivaroxaban was priced at £63.00 per 30-day supply.28
The 30-day drug costs of warfarin and aspirin were
£1.06 and £1.89, respectively, but warfarin patients
incurred an additional £38 monitoring cost monthly.6
Event costs were assigned as per-episode costs that
varied based on the disability level resulting from the
event where relevant. These costs were sourced either
from a population-based study of UK AF patient
costs29 or from the dabigatran NICE submission.6
Ongoing follow-up costs of disability management for
patients who were independent but with a history of
stroke, moderately disabled, or totally dependent were
set at £844, £4063, and £7587, respectively.29 Patients
with AMI history incurred an additional £20 cost every
model cycle based on the apixaban NICE submission.7
Discontinuation without an event incurred a cost of
£44 based on the cost of one visit to a general
practitioner.30 All cost inputs (Table III) are in 2013
pounds, and costs not originally reported in 2013
pounds have been adjusted for inﬂation according the
inﬂation index from the Personal Social Service
Research Unit.31
Utility Inputs
Patient survival was adjusted to account for
quality-of-life effects using utility values. Health
state utility and quality-of-life decrements for clinical
events were based on previously published values for
the UK setting.16 The baseline utility of a population
with AF was 0.81.32 A utility decrement was applied
at the time of an event for one cycle: stroke (utility
decrement, 0.139), systemic embolism (utility
decrement, 0.120), ICH (utility decrement, 0.181),
ECH (utility decrement, 0.181), TIA (utility
decrement, 0.103), AMI (utility decrement, 0.125),
and minor bleeding (utility decrement, 0.004).32
Utility values corresponding to patient‘s disability
status were applied to all cycles in which patients
spent in that status: independent with stroke history
(utility value, 0.76), moderately dependent (utility
value, 0.39), and totally dependent (utility value,Volume 36 Number 12
Table II. Baseline Event Risk and Relative Treatment Efficacy
Annual
Risk for
Warfarin, %
Relative Risk (95% CI) vs Warfarin
Dabigatran Rivaroxaban Apixaban Aspirin No Treatment
IS (including uncertain
stroke) by CHADS2
score
0 0.62
0.71 (0.53–0.96)* 0.95 (0.76–1.18)* 0.80 (0.65–1.00)* 1.62 (0.99–2.65) 3.35 (2.23–5.03)
1 0.77
2 1.01
3–4 1.75
5–6 3.34
Systemic embolism 0.18 0.55 (0.25–1.24) 0.26 (0.10–0.71) 0.76 (0.62–0.86) 1.77 (0.66–4.77) 4.44 (1.78–11.08)
TIA 0.84 0.79 (0.59–1.07) Assumed to be the same as dabigatran 1.56 (0.86–2.83) 1.23 (0.59–2.58)
ICH (including HS) 0.80 0.28 (0.17–0.45) 0.72 (0.51–1.01) 0.42 (0.30–0.58) 0.51 (0.16–1.60) 1.23 (0.59–2.58)
ECH 2.84 1.07 (0.91–1.26) 1.21 (1.04–1.41) 0.79 (0.68–0.93) 1.14 (0.47–2.73) 0.61 (0.10–3.78)
Minor bleeds 16.37 0.87 (0.82–0.93) Assumed to be the same as dabigatran 0.63 (0.32–1.22) 0.55 (0.38–0.80)
AMI 0.64 1.28 (0.95–1.74) 0.94 (0.73–1.22) 0.88 (0.66–1.17) 1.42 (0.84–2.39) 1.57 (0.67–3.69)
Relative risk of AMI
history on future
AMI
3.11
AMI ¼ acute myocardial infarction; CHADS2 ¼ Congestive heart failure, Hypertension, Age475 years, Diabetes, and prior Stroke17; ECH ¼ extracranial hemorrhage;
HS ¼ hemorrhagic stroke; ICH ¼ intracranial hemorrhage; IS ¼ ischemic stroke; TIA ¼ transient ischemic attack.
*None of the Phase III trials studied whether the relative risk of IS for new oral anticoagulants was dependent or independent of CHADS2 score, and they were not
powered to determine the association. The Phase III trials for dabigatran10 and apixaban12 explored whether the primary efﬁcacy end point (relative risk of stroke and
systemic embolism) was dependent on CHADS2 score, and both found the interaction statistically nonsigniﬁcant. Y.
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Table III. Model Cost Inputs
2013 Costs, £ Reference
Drug costs per day
Dabigatran 2.20 28
Rivaroxaban 2.10 28
Apixaban 2.20 28
Warfarin 0.04 28
Aspirin 0.09 28
Monitoring cost per year
Warfarin 455.22 6
Event cost per episode
Fatal IS 3376.36 29
IS, independent 3753.84 29
IS, moderately dependent 19,583.75 29
IS, totally dependent 26,748.16 29
Systemic embolism, fatal 438.87 6*
Systemic embolism, nonfatal 2603.59 6*
TIA 1174.39 Data on ﬁle†
ICH, fatal 1757.16 29
ICH, independent 10,930.39 29
ICH, moderately dependent 28,081.49 29
ICH, totally dependent 47,500.78 29
ECH (nonbrain), fatal 2,031.96 6*
ECH (nonbrain), nonfatal, nongastrointestinal 2313.93 6*
ECH (nonbrain), nonfatal, gastrointestinal 1748.89 6*
Minor bleeding 92.16 6*
AMI, fatal 3243.24 6*
AMI, nonfatal 3243.24 6*
Follow-up cost per quarter
Independent with stroke history 331.00 29
Moderately dependent with stroke history 2867.75 29
Totally dependent with stroke history 6088.50 29
AMI history 19.95 7
One-time discontinuation cost
All comparator 44.05 30
AMI ¼ acute myocardial infarction; ECH ¼ extracranial hemorrhage; ICH ¼ intracranial hemorrhage; IS ¼ ischemic stroke;
TIA ¼ transient ischemic attack.
*Mean is an assumption from the manufacturer submission to the National Institute of Health and Care Excellence as part of
TA249, 2009/2010 cost inﬂated to 2012/2013. SE is assumed 20% of mean.
†UK Cost of Stroke Study based on OXVASC. The 2008/2009 cost inﬂated to 2012/2013 by the inﬂation factor of 1.10.
Clinical Therapeutics0.11).33 In addition, a long-term utility effect of
AMI history was considered in the model, with a
disutility of 0.037 applied to patients with AMI
history.342020Model Analyses
The base case analyses compared clinical and
cost-effectiveness of the 3 NOACs—dabigatran, apixa-
ban, rivaroxaban—and warfarin. An incremental cost-Volume 36 Number 12
Y. Zheng et al.effectiveness ratio (ICER) was used to measure cost-
effectiveness; ICER compares the additional cost of a
treatment to the incremental clinical beneﬁt. A net
monetary beneﬁt (NMB) analysis35 was also conducted
that converts clinical outcomes to monetary values
based on willingness-to-pay (WTP) for the gain of
one additional unit of health beneﬁt, such as life-year
(LY) or quality-adjust life-year (QALY), with a higher
NMB indicating greater cost-effectiveness. Different
model parameters were tested in 1-way deterministic
sensitivity analyses. Finally, a probabilistic sensitivity
analysis (PSA) was undertaken, varying all clinical,
cost, and utility parameters in the model simultane-
ously, including all 3 NOACs and warfarin.
RESULTS
Base-Case Analysis
In the base case for a lifetime analysis (Table IV),
the patients treated with dabigatran experienced theTable IV. Deterministic Model Outcomes
Comparator Dabigatran Riva
Clinical Events (per 100 Patient-years)
IS 2.33
Systemic embolism 0.23
ICH (including HS) 0.50
TIA 1.15
ECH 4.09
AMI 1.19
2013 Costs, £
Drug costs 5669 5
Event costs 3237 3
Follow-up costs 14,436 1
Total costs 23,342 2
LYs 10.04
QALYs 7.68
Incremental (Dabigatran vs Comparators)
Total costs, ₤ 
LYs
QALYs
ICERs (costs per QALYs) Dabi
do
AMI ¼ acute myocardial infarction; ECH ¼ extracranial hemorr
effectiveness ratio; ICH ¼ intracranial hemorrhage; IS ¼ ischem
TIA ¼ transient ischemic attack.
December 2014lowest mean number of IS and ICH events per 100
patient-years among the 3 NOACs. Patients taking
rivaroxaban had the fewest systemic embolism
events, whereas patients taking apixaban had the
lowest AMI rate. Patients treated with NOACs gen-
erally experienced fewer events compared with pa-
tients taking warfarin, with some exceptions.
Compared with patients taking warfarin, patients
taking rivaroxaban and dabigatran had higher ECH
rates, and patients taking dabigatran had a slightly
higher AMI rate.
Table IV presents mean total costs and disag-
gregated costs, total LYs, QALYs, and incremental
cost per QALY gained (ie, ICER) per AF patient
comparing dabigatran to rivaroxaban and apixaban.
Despite slightly higher drug acquisition costs
compared with the other NOACs, dabigatran’s total
lifetime costs (£23,342) were lower than those for
rivaroxaban (£25,220) and apixaban (£24,014)roxaban Apixaban Warfarin
2.73 2.48 2.85
0.19 0.26 0.31
0.90 0.63 1.15
1.15 1.15 1.31
4.41 3.36 3.87
0.95 0.91 0.99
237 5602 153
944 3340 4344
6,039 15,072 20,184
5,220 24,014 24,680
9.83 9.97 9.73
7.47 7.63 7.36
1877 672 1338
0.20 0.06 0.30
0.21 0.05 0.32
gatran is
minant
Dabigatran is
dominant
Dabigatran is
dominant
hage; HS ¼ hemorrhagic stroke; ICER ¼ incremental cost-
ic stroke; LY ¼ life-year; QALY ¼ quality-adjusted life-year;
2021
Clinical Therapeuticsbecause dabigatran’s cost offsets were associated with
reduction in events and long-term disability. Treat-
ment with dabigatran also resulted in more QALYs
(7.68 QALYs) compared with rivaroxaban (7.47
QALYs) and apixaban (7.63 QALYs) and more LYs
(10.04 LYs) compared with rivaroxaban (9.83 LYs)
and apixaban (9.97 LYs). Thus, in the base case,
dabigatran dominated both rivaroxaban and apixa-
ban, yielding more QALYs at less cost.
The incremental NMBs of dabigatran, rivarox-
aban, apixaban, and warfarin were compared.
At every WTP threshold, dabigatran had the high-
est incremental NMB (Figure 1). At the NICE
WTP threshold of £25,000 per QALY, the
incremental NMB versus warfarin was £9217 for
dabigatran, £7203 for apixaban, and £2100 for
rivaroxaban.
Deterministic Sensitivity Analysis and
Scenario Analysis
Table V presents the effects of varying model
input parameters on the base case NMB outcome,
for a WTP threshold of £25,000 per QALY. The
results are presented graphically through tornado
diagrams in Figure 2. The most signiﬁcant driver of
cost-effectiveness was the RR of IS. When varied
from the upper to lower limits of the 95% CI, the4000
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Anticoagulation Therapy.
2022NMB ranged from £4630 to £8943 for dabigatran
versus rivaroxaban and from £474 to £3839 for
dabigatran versus apixaban. Similarly, varying the
RR of ICH from the upper to lower limits of the
95% CI, the NMB for dabigatran versus rivarox-
aban ranged from £5049 to £8479 and from £55
to £3375 for dabigatran versus apixaban. The
model NMB results were relatively robust to the
variations in the RR of ECH, AMI, and the long-
term utility of AMI history. The NMB accrued
relatively steadily over time, with higher NMBs for
longer time horizons. The NMB of dabigatran
versus rivaroxaban was £1290 under a 5-year time
horizon and £3319 under a 10-year time horizon.
The NMB of dabigatran versus apixaban was £239
under a 5-year time horizon and £815 under a 10-
year time horizon. The model outcome is slightly
more favorable for dabigatran when 150 mg BID
dosing (the approved dosing for dabigatran in
certain markets, including the United States) is used
instead of the approved dosing in the European
Union, with an NMB of £7256 versus rivaroxaban
and £2152 versus apixaban. In all sensitivity anal-
yses performed, dabigatran had a positive NMB at a
WTP of £25,000 per QALY compared with rivar-
oxaban. Compared with apixaban, dabigatran re-
mained the preferred treatment option (positiveTP (£)
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Table V. Deterministic Sensitivity Analysis and Scenario Analysis Results (NMB)
Parameter Base Case Value SA Value
NMB of Dabigatran, £
vs Rivaroxaban vs Apixaban
Base case 7117 2014
CHADS2 distribution RE-LY CHADS2 distribution CHADS2 score ¼ 2 7292 2094
CHADS2 score ¼ 5 7485 2167
RR of IS (dabigatran vs warfarin) 0.71 0.53 8943 3839
0.96 4630 474
RR of ICH (dabigatran vs warfarin) 0.28 0.17 8479 3375
0.45 5049 55
RR of ECH (dabigatran vs warfarin) 1.07 0.91 7371 2267
1.26 6816 1712
RR of AMI (dabigatran vs warfarin) 1.28 0.95 7315 2211
1.74 6839 1735
NOAC discontinuation rates, % 21 at year 2 for all Dabigatran, 21; rivaroxaban, 18; apixaban, 14 7094 1411
Post-IS disability Based on RE-LY for all* Varied by treatment† 5741 754
Discontinuation rate and post-IS
disability
As in the preceding
2 rows
As in the preceding 2 rows 5501 600
Disutility of AMI history 0.037 0
0.088 (upper limit of the 95% CI)
7215 2093
6982 1904
Annual discount rate on health, % 3.50 0 9967 2840
Annual discount rate of cost, % 3.50 0 7811 2281
Time horizon
5 Years Lifetime 1290 239
10 Years Lifetime 3319 815
Dabigatran dosing Per EU labeling 150 mg BID 7256 2152
AMI ¼ acute myocardial infarction; CHADS2 ¼ Congestive heart failure, Hypertension, Age475 years, Diabetes, and prior Stroke17; ECH ¼ extracranial hemorrhage;
EU ¼ European Union; ICH ¼ intracranial hemorrhage; IS ¼ ischemic stroke; NMB ¼ net monetary beneﬁt; RE-LY ¼ Randomized Evaluation of Long-Term
Anticoagulation Therapy; RR ¼ relative risk; SA ¼ sensitivity analysis.
*For all comparators based on the RE-LY warfarin arm, independent, 53.9%; moderately dependent, 19.7%; totally dependent, 4.3%; and fatal, 22.2%.
†For dabigatran, independent, 35%; moderately dependent, 22%; totally dependent, 8%; and fatal, 35%. For rivaroxaban, independent, 49%; moderately dependent,
18%; totally dependent, 8%; and fatal, 27%. For apixaban, independent, 53%; moderately dependent, 21%; totally dependent, 8%; and fatal, 18%. For second-line
aspirin, independent, 36%; moderately dependent, 38%; totally dependent, 15%; and fatal, 11%. Data are based on apixaban UK cost-effectiveness model
publication.44
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Figure 2. Deterministic sensitivity analysis and scenario analysis results (net monetary benefit) for dabigatran
versus rivaroxaban (A) and dabigatran versus apixaban (B). AMI ¼ acute myocardial infarction;
CHADS2 ¼ Congestive heart failure, Hypertension, Age 475 years, Diabetes, and prior Stroke;
ECH ¼ extracranial hemorrhage; ICH ¼ intracranial hemorrhage; IS ¼ ischemic stroke; NOAC ¼
new oral anticoagulant; RR ¼ relative risk.
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the 95% CI was used for the RR of IS or ICH or
when both treatment discontinuation rates and
post-IS disability were assumed to favor apixaban.
Probabilistic Sensitivity Analyses
A PSA simulation of dabigatran, apixaban, and
rivaroxaban versus warfarin treatment revealed that
dabigatran and apixaban provided more QALYs than
warfarin in all simulation runs, whereas rivaroxaban
provided more QALYs than warfarin in 97% of
simulation runs. Compared with warfarin, dabigatran
decreased the total cost in 97% of simulation runs,
whereas apixaban and rivaroxaban decreased cost in
81% and 17% of simulation runs. At the NICE WTP
threshold of £25,000 per QALY, the most cost-
effective treatment option was dabigatran in 92% of
the model runs and apixaban in 8% of the model
runs, whereas rivaroxaban and warfarin were not the
most cost-effective treatment at this WTP in any of the
model runs. Across different WTP thresholds, dabiga-
tran yielded the highest NMB (Figure 1).
DISCUSSION
Interpretation of the Model Results
This study compared the clinical and economic
outcomes of the NOACs during the patient lifetime.
Among the 3 NOACs analyzed in the model, patients
taking dabigatran had the highest numbers of LYs and
QALYs, whereas patients taking rivaroxaban had the
lowest number of LYs and QALYs, with patients
taking apixaban ranking in the middle. In terms of
cost, patients taking rivaroxaban had the highest total
cost, whereas patients taking dabigatran had the
lowest, with patients taking apixaban again ranking
in the middle. As a result, dabigatran was found to be
economically dominant over rivaroxaban and apixa-
ban in the UK setting. Similar to previous studies, the
key drivers of cost-effectiveness of dabigatran relative
to other NOACs were the reductions in the IS and
ICH/HS rates. On the basis of the ITC, dabigatran
was found to be more effective in reducing the risk of
IS and ICH/HS, which provided the foundation for the
favorable economic outcome. Similarly, because rivar-
oxaban had the lowest efﬁcacy in reducing IS and
ICH/HS among the NOACs, patients taking rivarox-
aban were predicted to have the lowest number of LYs
and QALYs. Several ITCs36–38 and one mixed treat-
ment comparison conducted by the Canadian AgencyDecember 2014for Drugs and Technologies in Health39 comparing
the clinical efﬁcacy of the NOACs have been
published. Although the outcomes from these studies
cannot be used directly as model inputs because of
differences in the event deﬁnitions, a similar trend of
the relative efﬁcacy among NOACs was found in these
studies.
As indicated by the deterministic sensitivity analy-
sis, the RR of IS had a slightly bigger effect on NMB
compared with the RR of ICH. This model also
considered the long-term effect of AMI on future
AMI risk, utility, and cost, yet neither the RR for
AMI nor the long-term utility effect of AMI was found
to be a driver of model outcome. Overall, the
deterministic sensitivity analysis and PSA results that
dabigatran is the most cost-effective among 92% of
the PSA runs at a WTP of £25,000 per QALY
indicated that the probability of dabigatran being
more cost-effective than the other 2 NOACs was
high. The model outcome is reported in the form of
NMB because it is better suited to compare multiple
comparators, rank them at different WTP levels, and
enhance the 1-way sensitivity analysis.40
Brief Comparison of the Model Results Versus
Similar Studies
The trends in relative QALYs and costs between
comparators found in this analysis were similar to
those in other published studies. In a recent study by
Coyle et al,41 dabigatran 150 mg was found to have
equal QALY outcome to apixaban but with lower
total cost. Both apixaban and dabigatran 150 mg
were found to dominate rivaroxaban and dabigatran
110 mg. In this study, apixaban and dabigatran 150
mg were associated with the highest relative number
of QALYs (6.617 QALYs for both), and dabigatran
150 mg had the smallest relative cost of all NOAC
comparators. In previous iterations of the current
model, dabigatran was found to dominate rivaro-
xaban.23
Other published comparisons of NOACs for the
treatment of AF have found apixaban to offer an
incremental QALY beneﬁt over dabigatran. Harring-
ton et al42 found apixaban to be associated with 8.47
QALYs versus 8.41 QALYs for dabigatran. This
ﬁnding was primarily driven by results from an ITC,
claiming the efﬁcacy of apixaban to be superior over
dabigatran in all measures, including stroke reduction,
which contradicted ﬁndings from our ITC and the2025
Clinical Therapeuticspreviously published ITC and mixed treatment
comparison.36–39 Pink et al43 evaluated the QALY
beneﬁt of dabigatran 150 mg, rivaroxaban, apixaban,
and warfarin and found apixaban to be associated with
highest net health beneﬁt (0.130 QALYs) compared
with dabigatran 150 mg (0.106 QALYs) and
rivaroxaban (0.095 QALYs). Although the worse
health outcome in rivaroxaban was mainly attri-
butable to inferior efﬁcacy as indicated by the ITC
conducted in this study, the difference between
dabigatran and apixaban was largely driven by the
higher treatment discontinuation due to nonclinical
reasons for dabigatran (7.8% higher in year 1 and
1.7% higher in all years after under a lifetime horizon).
In a recent manufacturer submission to NICE,
apixaban was found to be more cost-effective than
dabigatran and rivaroxaban. This ﬁnding was driven
by apixaban’s relatively high number of QALYs (5.86
QALYs) compared with dabigatran, rivaroxaban, and
warfarin (5.79, 5.81, and 5.7 QALYs, respectively),
which offset apixaban’s relatively higher cost.7
However, this ﬁnding was based on the assumptions
that both the severity of stroke and discontinuation
rates not due to events were dependent on treatment
type. The NICE Evidence Review Group removed
each of these assumptions in a reanalysis of the data
out of concerns over insufﬁcient data supporting these
assumptions and thus their clinical appropriateness.26
In that reanalysis, dabigatran was found to have a
lower ICER versus warfarin compared with apixaban
when severity of stroke was assumed to be
independent of treatment (£11,664 per QALY vs
£11,863 per QALY in 2010-2011 cost) and when
discontinuation was assumed to be independent of
treatment (£10,552 per QALY vs £11,008 per QALY
in 2010-2011 cost).26 These ﬁndings are consistent
with the sensitivity analyses presented in this study,
where apixaban became the preferred treatment only
when both discontinuation rate and post-IS disability
were assumed to favor apixaban.
The current model expands on a model that has
been previously reviewed in multiple contexts,6,15,16,23
facilitating the comparison among the NOACs and
understanding of the results compared with other
reported cost-effectiveness analyses. By allowing dis-
ability level after IS or ICH to be independent of
treatment and increasing the risk of future AMI based
on history of AMI, this study reﬂected an updated
understanding of clinical events’ long-term2026consequences in event risk, utility, and costs. In
addition, by comparing dabigatran to apixaban, rivar-
oxaban, and warfarin data in common study popula-
tions (the SOT populations, wherever available), this
study contributed a meaningful analysis of the relevant
comparators in what has become a crowded ﬁeld of
treatment options.
The use of indirect comparison, however, repre-
sents a limitation of the analyses. Another key limi-
tation is that it extrapolates the efﬁcacy outcomes
from RCT with a median follow-up of 2 years beyond
the trial period and assumes continued clinical beneﬁt
with ongoing anticoagulation treatment. However,
using a lifetime horizon for the model analysis is
appropriate because the decision for AF patients to
undergo anticoagulation therapy should be lifelong
and the post-event disability persists.
CONCLUSION
This study provided a meaningful comparison of the
relevant treatments for AF in the United Kingdom, a
ﬁeld that has recently become crowded by multiple
new treatment options. The results of this analysis
indicated that dabigatran yields more total QALYs at
lower lifetime costs than apixaban and rivaroxaban,
dominating the other 2 NOACs.
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Table S1DAll dabigatran relative risks (RRs) were derived
directly based on a population (n ¼ 5990) that
combined patients age o80 years from the dabiga-
tran 150 mg BID group (n ¼ 5019/6076) and
patients age Z80 years from the dabigatran 110
mg BID group (n ¼ 971/6015) (Boehringer Ingel-
heim, data on ﬁle). For apixaban, the RRs for all events were derived
based on the 2 publications of the Apixaban for the
Prevention of Stroke in Subjects With Atrial Fibril-
lation (ARISTOTLE) trial.○ Ischemic stroke (IS), including uncertain
stroke, systemic embolism, and intracranial
hemorrhage (ICH), including hemorrhagic
stroke (HS) (reported as intracranial bleed-
ing), were based on the data of Lopes et al.24○ Extracranial hemorrhage (ECH) (reported as
major bleeding in other location than intra-
cranial) and acute myocardial infarction
(AMI) were derived from data based on the
study of Granger et al.12 For rivaroxaban, the unadjusted RRs for all events
were derived based on the Rivaroxaban Once-daily
oral direct factor Xa inhibition Compared with
vitamin K antagonism for prevention of stroke and
Embolism Trial in Atrial Fibrillation (ROCKET-
AF) trial publication and its Supplemental Appen-
dix.13 Reports of ICH included HS.ecember 2014As reported in a previous study, poor international
normalized ratio control was associated with in-
creased event risk.21 Following a similar approach,
patient-level warfarin data from the RE-LY trial were
analyzed using logistic regression, and odds ratios for
a 10% change in time in therapeutic range (TTR)
were derived. The difference in TTR between the
warfarin arms of the RE-LY and ROCKET-AF trials
was taken from an analysis conducted by the Division
of Biometrics of the Food and Drug Administration, in
which the ROCKET-AF trial population was adjusted
by demographic, disease-related, and geographic fac-
tors to the RE-LY population, leaving a residual
difference in TTR of 6.7% (RE-LY–FDA-adjusted
ROCKET-AF TTR, 64.4%–57.7%).22 The 10%
adjustment factor was ﬁrst scaled to the 6.7% TTR
difference between the 2 warfarin arms and was then
applied to the event rate of warfarin arm of the
ROCKET-AF trial to derive the TTR-adjusted event
rate. Finally, the event rate of the rivaroxaban arm
was compared with the TTR-adjusted event rate of the
warfarin arm from the ROCKET-AF trial to derive the
TTR-adjusted RR. For example, for IS that included
uncertain stroke, the unadjusted RR for rivaroxaban
versus warfarin of 0.91 was ﬁrst adjusted by 1.046
(1.070⋀[6.7%/10%]), giving a TTR-adjusted RR of
0.95, and then this adjusted RR was used in the
indirect comparison.2028.e1
Supplemental Table S1. Detailed Data on the Indirect Treatment Comparison
RR (95% CI) (vs Warfarin)
RR for 10%
Difference
in TTR*Population Dabigatran Apixaban
Rivaroxaban
Unadjusted TTR Adjusted
IS (including
uncertain stroke)
SOT 0.71 (0.53–0.96) 0.80 (0.65–1.00)† 0.91 (0.73–1.13)‡ 0.95 (0.76–1.18) 1.070
Systemic embolism SOT 0.55 (0.25–1.24) 0.76 (0.62–0.86)§ 0.23 (0.09–0.60)|| 0.26 (0.10–0.71) 1.264
TIA ITT 0.79 (0.59–1.07) NA¶ NA NA¶ NA
ICH (including HS) SOT 0.28 (0.17–0.45) 0.42 (0.30–0.58) 0.67 (0.47–0.93) 0.72 (0.51–1.01) 1.137
ECH SOT 1.07 (0.91–1.26) 0.79 (0.68–0.93) 1.13 (0.97–1.31)# 1.21 (1.04–1.41) 1.111
Minor bleeding ITT 0.87 (0.82–0.93) NA¶ NA NA¶ NA
AMI ITT 1.28 (0.95–1.74) 0.88 (0.66–1.17) 0.91 (0.71–1.17)** 0.94 (0.73–1.22) 1.051
AMI ¼ acute myocardial infarction; ECH ¼ extracranial hemorrhage; ICH ¼ intracranial hemorrhage; IS ¼ ischemic stroke;
ITT ¼ intent to treat; NA ¼ not applicable; NR ¼ not reported; RR ¼ relative risk; SOT ¼ safety on treatment; TTR ¼ time in
therapeutic range.
*The relationship of TTR with the clinical outcomes was derived using logistic regression of patient-level warfarin data from
the Randomized Evaluation of Long-Term Anticoagulation Therapy trial.23
†In the Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE) trial, the event rates for the
primary efﬁcacy end point (stroke or systemic embolism) for the SOT population were reported as 0.96% vs. 1.39%
(apixaban vs warfarin).24 Separately, 76% of the primary efﬁcacy events in the apixaban arm were reported to be IS
(including uncertain stroke), whereas 66% in the warfarin arm were reported to be IS (including uncertain stroke).12 The
estimated event rates for IS, including uncertain stroke, were 0.73% versus 0.92% for apixaban and warfarin, respectively,
and the RRs were derived based on these rates.
‡In the Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke
and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial, the event numbers of all strokes were reported as 184 versus
221 (rivaroxaban vs warfarin) for the SOT population (n¼7061 for rivaroxaban and n¼7082 for warfarin).13 Separately, 29
of these events in the rivaroxaban arm were hemorrhagic stroke, whereas 50 in the warfarin arm were reported to be
hemorrhagic stroke.13 The event numbers for IS (including uncertain stroke) were estimated to be 155 for rivaroxaban and
171 for warfarin, which were then used to calculate the event risk and eventually the RR.
§In the ARISTOTLE trial, the event rates for the primary efﬁcacy end point (stroke or systemic embolism) for the SOT
population were reported as 0.96% versus 1.39% (apixaban vs warfarin).24 Separately, 7% of the primary efﬁcacy events in
the apixaban arm were reported to be systemic embolism, whereas 6% in the warfarin arm were reported to be systemic
embolism.12 The estimated event rates for systemic embolism were 0.07% versus 0.09% for apixaban and warfarin,
respectively, and the RRs were derived based on these rates.
||In the ROCKET-AF trial, the event numbers of the primary end point (stroke or systemic embolism) were reported as 189
versus 243 (rivaroxaban vs warfarin) for the SOT population.13 Separately, 184 of these events in the rivaroxaban arm were
stroke, whereas 221 in the warfarin arm were reported to be stroke.13 The event numbers for systemic embolism were
estimated to be 5 for rivaroxaban and 22 for warfarin, which were then used to calculate the event risk and eventually
the RR.
¶Assumed to be the same as dabigatran.
#In the ROCKET-AF trial, the event numbers of major bleeding were reported as 395 versus 386 (rivaroxaban vs warfarin) for
the SOT population.13 Separately, 55 of these events in the rivaroxaban arm were ICH, whereas 84 in the warfarin arm were
reported to be ICH.13 The event numbers for ECH were estimated to be 340 for rivaroxaban and 302 for warfarin, which
were then used to calculate the event risk and eventually the RR.
**From the ROCKET-AF trial presentation.45
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